Delving into the Latest Updates on VT-1092 with Synapse

Overview

Basic Info

Drug Type

Oncolytic virus

Synonyms

VT 1092, VT-1092, VT1092

Target

Cytokines

Mechanism

Cytokines modulators

Therapeutic Areas

NeoplasmsNervous System DiseasesSkin and Musculoskeletal Diseases

Active Indication

GliomaMelanomaMalignant Solid Neoplasm+ [1]

Inactive Indication-

Originator Organization

Beijing WellGene Biotech Co., Ltd.

Active Organization

Beijing WellGene Biotech Co., Ltd.

Inactive Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

主要目的：评价 VT1092 瘤内单次给药及多次给药在复发或转移性实体瘤受试者中的安全性及耐受性，探索人体的最大耐受剂量（MTD）及剂量限制性毒性（DLT），为本品的后续拓展试验及 Ⅱ 期临床研究推荐安全剂量范围。次要目的：评估 VT1092 瘤内单次给药及多次给药在人体内的生物分布及生物效应。初步评价 VT1092 治疗复发或转移性实体瘤的客观有效率（ORR），疾病控制率（DCR）。

[Translation]

Primary purpose: To evaluate the safety and tolerability of single and multiple intratumoral administration of VT1092 in subjects with recurrent or metastatic solid tumors, explore the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) in humans, and recommend a safe dose range for subsequent extended trials and Phase II clinical studies of this product. Secondary purpose: To evaluate the biodistribution and biological effects of single and multiple intratumoral administration of VT1092 in humans. Preliminary evaluation of the objective response rate (ORR) and disease control rate (DCR) of VT1092 in the treatment of recurrent or metastatic solid tumors.

Start Date27 Jun 2022

Sponsor / Collaborator

Beijing WellGene Biotech Co., Ltd.

100 Clinical Results associated with VT-1092

Login to view more data

100 Translational Medicine associated with VT-1092

Login to view more data

100 Patents (Medical) associated with VT-1092

Login to view more data

100 Deals associated with VT-1092

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Glioma	Phase 2	CN	Beijing WellGene Biotech Co., Ltd.	-
Melanoma	Phase 2	CN	Beijing WellGene Biotech Co., Ltd.	-
Malignant Solid Neoplasm	Phase 1	CN	Beijing WellGene Biotech Co., Ltd.	27 Jun 2022
Sarcoma	Phase 1	-	Beijing WellGene Biotech Co., Ltd.	-